NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017Mary B. Daly, Susan Darlow, Shaveta Vinayak et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 660
Genetic/Familial High-Risk Assessment: Breast and OvarianMary B. Daly, Jeffrey N. Weitzel, Jennifer E. Axilbund et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 650
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerRowan Miller, Lucy Yates, Alexandra Léary et al.|Annals of Oncology|2020Cited by 478
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Panagiotis A. Konstantinopoulos, D. Gulhan et al.|Nature Communications|2020Cited by 342
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015Mary B. Daly, Susan Darlow, Robert Pilarski et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 293